Request Demo
Last update 18 Nov 2025
ALMB-0166
Last update 18 Nov 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms ALMB 0166, ALMB-0166, ALMB0166 |
Target |
Action inhibitors |
Mechanism GJA1 inhibitors(Gap junction alpha-1 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Login to view timeline
Related
2
Clinical Trials associated with ALMB-0166NCT05524103
A Phase Ⅰ, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury
ACTRN12619001689167
A Phase 1 Single Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALMB-0166 Administered to Healthy Subjects
100 Clinical Results associated with ALMB-0166
Login to view more data
100 Translational Medicine associated with ALMB-0166
Login to view more data
100 Patents (Medical) associated with ALMB-0166
Login to view more data
100 Deals associated with ALMB-0166
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| acute spinal cord injury | Phase 2 | United States | 10 Aug 2022 | |
| Osteoarthritis | Phase 2 | United States | - | |
| Parkinson Disease | Phase 2 | United States | - | |
| Spinal Cord Injuries | Phase 2 | China | - | |
| Stroke | Phase 2 | United States | - | |
| Stroke | Phase 2 | China | - | |
| Ischemic stroke | IND Approval | China | 15 Nov 2023 | |
| Alzheimer Disease | Preclinical | United States | 01 Sep 2025 | |
| Epilepsy | Preclinical | United States | 01 May 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free